As to TLR2, Kim et al. (2018) showed that exposure to an anti-TLR2 treatment led to amelioration of pathology and symptoms, with reduced accumulation of alpha-synuclein in neurons and astroglia, in an alpha-synucleinopathy transgenic mouse model (Figure 1). Here, SNCA is linked to synucleinopathy.